Press Releases

July 10, 2019

Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration

Loughborough, England , July 10, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

June 17, 2019

Nemaura Provides Fiscal 2019 Year-End Business Update

Readies launch of SugarBEAT® in United Kingdom and Germany following CE Mark approval On track to submit FDA application...

June 14, 2019

Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report

Loughborough, England, June 14, 2019 (GLOBE NEWSWIRE) — – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

May 29, 2019

Nemaura Announces CE Mark Approval of SugarBEAT®

SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc....

May 2, 2019

Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®

Allows 3rd Party Applications to Directly access SugarBEAT® CGM Data Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) —...

April 23, 2019

Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

Final step required prior to filing de novo application to the U.S. Food and Drug Administration Loughborough, England ,...

April 18, 2019

Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

Enhances Product Capabilities in Advance of CE Mark Approval April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a...

March 28, 2019

Nemaura CEO Provides Update to Shareholders

Announces SugarBEAT® Awaiting CE Mark Approval; On Track for FDA submission in Q2 2019 Loughborough, England, March 28, 2019...

March 12, 2019

Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) — Loughborough, England – March 12, 2019 – Nemaura Medical, Inc....

February 12, 2019

Nemaura Reports Third Quarter 2018 Financial Results

Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as...